Navigation Links
Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
Date:5/6/2008

ill occur in the future. Forward-looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.

CONTACT:

Genta Investor Relations

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Elizabeth Brown Joins Argenta TEC
2. Syngenta To Build Major Global Biotech Research Center in Beijing, China
3. Genta Restructures Operations to Focus on Priority Initiatives
4. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
5. Auditors for Genta Incorporated Express Going Concern Qualification
6. Genta Announces Senior Management Changes
7. Genta Announces Common Stock Offering of Approximately $3.1 Million
8. Genta Incorporated to Present at the BIO CEO & Investor Conference
9. Genta Receives Notice of Non-Compliance With NASDAQ Rule
10. Genta Receives NASDAQ Non-Compliance Notice
11. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 Biscayne Pharmaceuticals, ... potential of its growth hormone-releasing hormone (GHRH) technology will ... 2015 ASCO Annual Meeting. The data show that the ... anti-cancer GHRH blockers, is present on many primary breast ... suggest that GHRH antagonists could have broad anti-cancer potential ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 CD-adapco, ... Aided Engineering software, announced today it is joining ... CD-adapco will provide state-of-the-art engineering simulation tools for ... their expertise and experiences in analyzing particle flow ... members and advance the understanding of flow modeling ...
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo ... EMR/EHR Clinical Data Integration with EDC Systems ” at ... DC on June 14th-18th. , During the presentation, Glenn ... with EDC, and will examine the value of patient ... electronic health records/electronic medical records integration. , The ...
(Date:5/28/2015)... Global futurist and keynote speaker Jack ... audiences if they are ready for a wide ... fuel cells, rapid health care diagnostic tools, affordable ... driverless cars, artificial intelligence masquerading as overly attentive ... , While the majority of organizations and ...
Breaking Biology Technology:Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2
... , , SEATTLE and ATLANTA, ... it has signed a lease agreement with Majestic Realty Co. to build ... to manufacture PROVENGE(R) (sipuleucel-T) for patients with advanced prostate cancer. The ... , , If approved by the U.S. Food and ...
... , , , , ... results for its first fiscal quarter ended June 30, 2009. Net sales increased 22% ... year. , , Net loss for the quarter was ... of the prior fiscal year of $587,000 or $0.05 per share. The prior ...
... BOZEN, Italy, August 10 , ... Robotics , Health Robotics today announced ... for Health Robotics, CytoCare Robot. The,agreement enables McKesson to achieve ... Oncology I.V. admixtures. , "We are ...
Cached Biology Technology:Dendreon Signs Lease for New Manufacturing Facility in Atlanta 2Dendreon Signs Lease for New Manufacturing Facility in Atlanta 3Imagenetix, Inc. Reports First Quarter 2010 Results 2Imagenetix, Inc. Reports First Quarter 2010 Results 3Imagenetix, Inc. Reports First Quarter 2010 Results 4Imagenetix, Inc. Reports First Quarter 2010 Results 5McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 2McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 3
(Date:5/25/2015)... 25, 2015  Australia,s market for wearable technologies is ... saw the advent of several trials and prototypes. The ... is expected to ignite interest in wearables as well ... Australia . This in turn will spur greater ... new partnerships amongst vendors and distributors. ...
(Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
(Date:5/21/2015)... BOSTON , May 21, 2015 ... scientific potential of music for health, today announced a ... (BerkleeICE) . The partnership will center on collaboration on ...  As a first step in the collaboration, The Sync ... course on "Music as Medicine" in the 2015-2016 academic ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3
... a seed to decide on the perfect time to germinate ... Plant biologists at The University of Nottingham have also discovered ... another important decision in the life cycle of plants ... the genetic mechanisms that plants use to detect and respond ...
... Scientists have used the latest computer-imaging technology ... million-year-old spider trapped inside an opaque piece of ... working with colleagues in Germany, created the intricate ... remarkable spider, which can barely be seen under ...
... German . , "Seeing something invisible with ... and Tolga Ergin. For about one year, both physicists and ... Center for Functional Nanostructures (CFN) have worked on refining the ... that it is also effective in the visible spectral range. ...
Cached Biology News:Nottingham scientists reveal genetic 'wiring' of seeds 2Imaging technology reveals intricate details of 49-million-year-old spider 2Karlsruhe invisibility cloak: Disappearing visibly 2
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Mycoplasma and virus tested...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
Biology Products: